Search

To assess the preventable visual impairment in children with nonprofound intellectual disability (ID). A total of 215 children with IDs (90 Down syndrome [DS], 125 nonprofound ID) and 116 age- and sex-matched healthy subjects were enrolled in this study. All participants underwent ophthalmologic examinations including cycloplegic refraction measurements, ocular movement evaluation, screening for strabismus (Hirschberg, Krimsky, or prism cover test), slit-lamp biomicroscopy, funduscopy, and intraocular pressure measurements. All data were recorded for statistical analysis. Ocular findings in decreasing prevalence were as follows: refractive errors 55 (61.1%), strabismus 30 (33.2%), cataract 7 (7.8%), and nystagmus 7 (7.8%) in children with DS; refractive errors 57 (45.6%), strabismus 19 (15.2%), cataract 7 (6.4%), nystagmus 5 (4%), and glaucoma 1 (0.8%) in children with other ID; and refractive errors 13 (11.2%) and strabismus 4 (3.5%) in controls. Cataracts, glaucoma, and nystagmus were not observed in the control group. The most common ophthalmic findings in children with DS compared with other ID and controls were with hyperopia (p0.03 and p0.001, respectively) and esotropia (p0.01 and p0.01, respectively). The pediatric population with ID has a high prevalence of preventable visual impairments, refractive errors, strabismus, and cataracts. The prevalence of strabismus and refractive errors was more frequent in children with DS. The importance of further health screenings including ophthalmic examinations should be utilized to implement appropriate care management and improve quality of life.

Purpose To report the results of switching from intravitreal bevacizumab to ranibizumab or vice versa in the treatment of choroidal neovascularization (CNV) due to age-related macular degeneration. Methods Twenty eyes of 18 patients that underwent switch from intravitreal bevacizumab to ranibizumab and 10 eyes of 8 patients that underwent switch from ranibizumab to bevacizumab were retrospectively analyzed. The results were compared with 41 eyes of 37 patients treated with ranibizumab only. All eyes initially received 3 injections of ranibizumab or bevacizumab, which were repeated as needed (PRN dosing). Anti–vascular endothelial growth factor therapies were switched because of general health insurance applications and cost problems. The main outcome measures were best-corrected visual acuity (BCVA), injection number, and central macular thickness (CMT) obtained by optical coherence tomography. Results Once all patients evaluated together at the final visit, the mean BCVA improved and CMT decreased. When switching groups were taken into consideration, switching yielded improved BCVA and reduced CMT following switching. After switching, BCVA continuously improved in the bevacizumab to ranibizumab group, but stayed stable in the ranibizumab to bevacizumab group. The CMT was reduced at the switching time in both groups, but did not change after the switch. Final visual acuity improved or stabilized in all eyes in the ranibizumab-only group. The BCVA worsened in 20% of eyes in the bevacizumab to ranibizumab group and in 40% of eyes in the ranibizumab to bevacizumab group. Conclusions The ranibizumab-only group and the switching from bevacizumab to ranibizumab group seemed superior to the ranibizumab to bevacizumab group.